| 摘要: |
| ［摘要］ 目的 观察经皮冠状动脉介入治疗（PCI）术前早期给予大剂量的瑞舒伐他汀对急性心肌梗死（AMI）患者冠状动脉微血管功能及其预后的影响。方法 选取2010-01～2014-01该院收治的行PCI的AMI患者94例，按随机数字表法随机分为对照组44例和观察组50例。对照组术后给予10 mg/d的瑞舒伐他汀，观察组于PCI术前早期给予40 mg的瑞舒伐他汀，术后处理同对照组。心肌及微血管的灌注情况采用TIMI心肌灌注分级（TMPG）进行评价，同时观察随访30 d内的主要心血管事件（MACE）的发生情况。结果 与术前比较两组术后的TMPG分级差异均有统计学意义（P<0.05），但观察组的TMPG改善比对照组显著（P<0.05）。随访30 d内观察组MACE的发生率为12.0%（6/50），明显低于对照组的34.1%（15/44）（P<0.05）；观察组术后TMPG 3级患者MACE的发生率为11.1%（3/27），明显低于对照组的42.9%（6/14）（P<0.05）。两组经随访均未发现肌毒性及肝毒性等不良反应发生。结论 PCI术前早期给予大剂量（40 mg）的瑞舒伐他汀对改善AMI患者的冠状动脉微血管功能及近期预后是有益处的。 |
| 关键词: 心肌梗死 血管介入术 瑞舒伐他汀 预后 |
| DOI：10.3969/j.issn.1674-3806.2015.03.15 |
| 分类号:R 542.2+2 |
| 基金项目: |
|
| Effects of early administration of large dose rosuvastatin on coronary microvascular function and short-term outcome in patients treated with primary PCI for acute myocardial infarction |
|
FAN Fu-rong, HOU Yan
|
|
Department of Pharmacy, General Hospital of Fushun Mining Bureau, Liaoning 113008, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the effects of early administration of large dose rosuvastatin（40 mg） on coronary microvascular function and short-term outcome in patients treated with primary percutaneous coronary intervention for acute myocardial infarction.Methods 94 consequent AMI patients treated with primary PCI were divided into control group（n=44） and observation group（n=50）. The infarct-related artery flow of epicardium was classified in compliance with the TIMI criteria. Myocardial and microvascular perfusion was assessed using the TMPG. The incidence of the MACE and the cytotoxicity and hepatotoxicity of rosuvastatin were respectively recorded in 30 days′ follow-up.Results TMPG in both observation group and control group improved immediately after PCI（P<0.05）. However, the post-PCI TMPG of observation group improved better than that of the control group（P<0.05）. The 30-day composite MACE rate was lower in the observation group than that in the control group（12.0% vs 34.1%，P<0.05）. The incidence of TMPG 3 patients was lower in observation group than that in the control group（11.1% vs 42.9%，P<0.05）. No cytotoxicity and hepatotoxicity happened in the two groups.Conclusion Early administration of large dose rosuvastatin（40 mg） can improve coronary microvascular function and short-term outcome in patients treated with primary percutaneous coronary intervention for acute myocardial infarction, and is safe. |
| Key words: Myocardial infarction Vascular intervention Rosuvastatin Prognosis |
